Report Detail

Request for Sample of this report

Pharma & Healthcare Global CD47 (IAP) Market Insights, Forecast to 2028

  • RnM4425202
    • |
  • 25 April, 2022
    • |
  • Global
    • |
  • 112 Pages
    • |
  • QYResearch
    • |
  • Pharma & Healthcare

Summary:

Market Analysis and Insights: Global CD47 (IAP) Market
The global CD47 (IAP) market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, CD47 Monoclonal Antibody accounting for % of the CD47 (IAP) global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Solid Tumor segment is altered to an % CAGR throughout this forecast period.
China CD47 (IAP) market size is valued at US$ million in 2021, while the North America and Europe CD47 (IAP) are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe CD47 (IAP) landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global CD47 (IAP) market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global CD47 (IAP) market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global CD47 (IAP) market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global CD47 (IAP) market.
Impact of Covid-19 Outbreak
This section of the report has explored the overall status of the Covid scenario and has offered valuable insights into the changes in supply chain disruption, fluctuations in demand, etc. The analysts have also focused on the key measures that the companies are opting to withstand the harsh scenario.
Segmental Analysis
The report has been segmented into product and application segments. The researchers have documented all the products present today in the CD47 (IAP) market. They have also shed light on the new product innovations and launches by the key players. In the segmental analysis, the analysts have provided revenue forecast figures based on type and application for the period 2017-2028. They have also discussed about the growth rate and potential of each segment for the period 2017-2028.
CD47 (IAP) Breakdown Data by Type
CD47 Monoclonal Antibody
CD47 Double Antibody
CD47 Fusion Protein
CD47 (IAP) Breakdown Data by Application
Solid Tumor
Lymphoma
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Competitive Landscape
This segment focuses on the key players operating in the industry. It underlines all the current and future activities by the prominent manufacturers. By understanding various initiatives being taken up by different players, readers will gain the ability to settle on correct business choices. The authors of the report have provided accurate revenue figures of the companies for the period 2017-2022. The clients are sure to gain the upper hand once they get hold of this report. Key players studied in the research report include:
Gilead
Innovent Biologics
Akeso, Inc
Arch Oncology
ImmuneOncia Therapeutics
I-MAB
Sorrento Therapeutics
Zai Lab
ImmuneOnco
Hengrui
Beijing Mab-works
Hanxbio
ALX Oncology
Surface Oncology
TG Therapeutics
EpicentRx
Frequently Asked Questions
What factors will challenge the CD47 (IAP) market growth?
Which end-use segment will expand at the fastest CAGR in the CD47 (IAP) market?
Which are the emerging players in the CD47 (IAP) market?
How concentrated is the CD47 (IAP) market?
Which factors are positively contributing to the CD47 (IAP) market growth?
Which are the novel product innovations in the CD47 (IAP) market?
Which product segment will emerge as the most lucrative in the CD47 (IAP) market?
Which factors are increasing the competition in the CD47 (IAP) market?
Which are the strategic measures taken by the CD47 (IAP) industry players?
Which region will witness inactive growth during the forecast period?
What key trends are likely to emerge in the CD47 (IAP) market in the coming years?


Table of Contents

    1 Report Business Overview

    • 1.1 Study Scope
    • 1.2 Market Analysis by Type
      • 1.2.1 Global CD47 (IAP) Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
      • 1.2.2 CD47 Monoclonal Antibody
      • 1.2.3 CD47 Double Antibody
      • 1.2.4 CD47 Fusion Protein
    • 1.3 Market by Application
      • 1.3.1 Global CD47 (IAP) Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
      • 1.3.2 Solid Tumor
      • 1.3.3 Lymphoma
      • 1.3.4 Others
    • 1.4 Study Objectives
    • 1.5 Years Considered

    2 Global Growth Trends

    • 2.1 Global CD47 (IAP) Market Perspective (2017-2028)
    • 2.2 CD47 (IAP) Growth Trends by Region
      • 2.2.1 CD47 (IAP) Market Size by Region: 2017 VS 2021 VS 2028
      • 2.2.2 CD47 (IAP) Historic Market Size by Region (2017-2022)
      • 2.2.3 CD47 (IAP) Forecasted Market Size by Region (2023-2028)
    • 2.3 CD47 (IAP) Market Dynamics
      • 2.3.1 CD47 (IAP) Industry Trends
      • 2.3.2 CD47 (IAP) Market Drivers
      • 2.3.3 CD47 (IAP) Market Challenges
      • 2.3.4 CD47 (IAP) Market Restraints

    3 Competition Landscape by Key Players

    • 3.1 Global Top CD47 (IAP) Players by Revenue
      • 3.1.1 Global Top CD47 (IAP) Players by Revenue (2017-2022)
      • 3.1.2 Global CD47 (IAP) Revenue Market Share by Players (2017-2022)
    • 3.2 Global CD47 (IAP) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    • 3.3 Players Covered: Ranking by CD47 (IAP) Revenue
    • 3.4 Global CD47 (IAP) Market Concentration Ratio
      • 3.4.1 Global CD47 (IAP) Market Concentration Ratio (CR5 and HHI)
      • 3.4.2 Global Top 10 and Top 5 Companies by CD47 (IAP) Revenue in 2021
    • 3.5 CD47 (IAP) Key Players Head office and Area Served
    • 3.6 Key Players CD47 (IAP) Product Solution and Service
    • 3.7 Date of Enter into CD47 (IAP) Market
    • 3.8 Mergers & Acquisitions, Expansion Plans

    4 CD47 (IAP) Breakdown Data by Type

    • 4.1 Global CD47 (IAP) Historic Market Size by Type (2017-2022)
    • 4.2 Global CD47 (IAP) Forecasted Market Size by Type (2023-2028)

    5 CD47 (IAP) Breakdown Data by Application

    • 5.1 Global CD47 (IAP) Historic Market Size by Application (2017-2022)
    • 5.2 Global CD47 (IAP) Forecasted Market Size by Application (2023-2028)

    6 North America

    • 6.1 North America CD47 (IAP) Market Size (2017-2028)
    • 6.2 North America CD47 (IAP) Market Size by Type
      • 6.2.1 North America CD47 (IAP) Market Size by Type (2017-2022)
      • 6.2.2 North America CD47 (IAP) Market Size by Type (2023-2028)
      • 6.2.3 North America CD47 (IAP) Market Share by Type (2017-2028)
    • 6.3 North America CD47 (IAP) Market Size by Application
      • 6.3.1 North America CD47 (IAP) Market Size by Application (2017-2022)
      • 6.3.2 North America CD47 (IAP) Market Size by Application (2023-2028)
      • 6.3.3 North America CD47 (IAP) Market Share by Application (2017-2028)
    • 6.4 North America CD47 (IAP) Market Size by Country
      • 6.4.1 North America CD47 (IAP) Market Size by Country (2017-2022)
      • 6.4.2 North America CD47 (IAP) Market Size by Country (2023-2028)
      • 6.4.3 United States
      • 6.4.4 Canada

    7 Europe

    • 7.1 Europe CD47 (IAP) Market Size (2017-2028)
    • 7.2 Europe CD47 (IAP) Market Size by Type
      • 7.2.1 Europe CD47 (IAP) Market Size by Type (2017-2022)
      • 7.2.2 Europe CD47 (IAP) Market Size by Type (2023-2028)
      • 7.2.3 Europe CD47 (IAP) Market Share by Type (2017-2028)
    • 7.3 Europe CD47 (IAP) Market Size by Application
      • 7.3.1 Europe CD47 (IAP) Market Size by Application (2017-2022)
      • 7.3.2 Europe CD47 (IAP) Market Size by Application (2023-2028)
      • 7.3.3 Europe CD47 (IAP) Market Share by Application (2017-2028)
    • 7.4 Europe CD47 (IAP) Market Size by Country
      • 7.4.1 Europe CD47 (IAP) Market Size by Country (2017-2022)
      • 7.4.2 Europe CD47 (IAP) Market Size by Country (2023-2028)
      • 7.4.3 Germany
      • 7.4.4 France
      • 7.4.5 U.K.
      • 7.4.6 Italy
      • 7.4.7 Russia
      • 7.4.8 Nordic Countries

    8 Asia-Pacific

    • 8.1 Asia-Pacific CD47 (IAP) Market Size (2017-2028)
    • 8.2 Asia-Pacific CD47 (IAP) Market Size by Type
      • 8.2.1 Asia-Pacific CD47 (IAP) Market Size by Type (2017-2022)
      • 8.2.2 Asia-Pacific CD47 (IAP) Market Size by Type (2023-2028)
      • 8.2.3 Asia-Pacific CD47 (IAP) Market Share by Type (2017-2028)
    • 8.3 Asia-Pacific CD47 (IAP) Market Size by Application
      • 8.3.1 Asia-Pacific CD47 (IAP) Market Size by Application (2017-2022)
      • 8.3.2 Asia-Pacific CD47 (IAP) Market Size by Application (2023-2028)
      • 8.3.3 Asia-Pacific CD47 (IAP) Market Share by Application (2017-2028)
    • 8.4 Asia-Pacific CD47 (IAP) Market Size by Region
      • 8.4.1 Asia-Pacific CD47 (IAP) Market Size by Region (2017-2022)
      • 8.4.2 Asia-Pacific CD47 (IAP) Market Size by Region (2023-2028)
      • 8.4.3 China
      • 8.4.4 Japan
      • 8.4.5 South Korea
      • 8.4.6 Southeast Asia
      • 8.4.7 India
      • 8.4.8 Australia

    9 Latin America

    • 9.1 Latin America CD47 (IAP) Market Size (2017-2028)
    • 9.2 Latin America CD47 (IAP) Market Size by Type
      • 9.2.1 Latin America CD47 (IAP) Market Size by Type (2017-2022)
      • 9.2.2 Latin America CD47 (IAP) Market Size by Type (2023-2028)
      • 9.2.3 Latin America CD47 (IAP) Market Share by Type (2017-2028)
    • 9.3 Latin America CD47 (IAP) Market Size by Application
      • 9.3.1 Latin America CD47 (IAP) Market Size by Application (2017-2022)
      • 9.3.2 Latin America CD47 (IAP) Market Size by Application (2023-2028)
      • 9.3.3 Latin America CD47 (IAP) Market Share by Application (2017-2028)
    • 9.4 Latin America CD47 (IAP) Market Size by Country
      • 9.4.1 Latin America CD47 (IAP) Market Size by Country (2017-2022)
      • 9.4.2 Latin America CD47 (IAP) Market Size by Country (2023-2028)
      • 9.4.3 Mexico
      • 9.4.4 Brazil

    10 Middle East & Africa

    • 10.1 Middle East & Africa CD47 (IAP) Market Size (2017-2028)
    • 10.2 Middle East & Africa CD47 (IAP) Market Size by Type
      • 10.2.1 Middle East & Africa CD47 (IAP) Market Size by Type (2017-2022)
      • 10.2.2 Middle East & Africa CD47 (IAP) Market Size by Type (2023-2028)
      • 10.2.3 Middle East & Africa CD47 (IAP) Market Share by Type (2017-2028)
    • 10.3 Middle East & Africa CD47 (IAP) Market Size by Application
      • 10.3.1 Middle East & Africa CD47 (IAP) Market Size by Application (2017-2022)
      • 10.3.2 Middle East & Africa CD47 (IAP) Market Size by Application (2023-2028)
      • 10.3.3 Middle East & Africa CD47 (IAP) Market Share by Application (2017-2028)
    • 10.4 Middle East & Africa CD47 (IAP) Market Size by Country
      • 10.4.1 Middle East & Africa CD47 (IAP) Market Size by Country (2017-2022)
      • 10.4.2 Middle East & Africa CD47 (IAP) Market Size by Country (2023-2028)
      • 10.4.3 Turkey
      • 10.4.4 Saudi Arabia
      • 10.4.5 UAE

    11 Key Players Profiles

    • 11.1 Gilead
      • 11.1.1 Gilead Company Details
      • 11.1.2 Gilead Business Overview
      • 11.1.3 Gilead CD47 (IAP) Introduction
      • 11.1.4 Gilead Revenue in CD47 (IAP) Business (2017-2022)
      • 11.1.5 Gilead Recent Developments
    • 11.2 Innovent Biologics
      • 11.2.1 Innovent Biologics Company Details
      • 11.2.2 Innovent Biologics Business Overview
      • 11.2.3 Innovent Biologics CD47 (IAP) Introduction
      • 11.2.4 Innovent Biologics Revenue in CD47 (IAP) Business (2017-2022)
      • 11.2.5 Innovent Biologics Recent Developments
    • 11.3 Akeso, Inc
      • 11.3.1 Akeso, Inc Company Details
      • 11.3.2 Akeso, Inc Business Overview
      • 11.3.3 Akeso, Inc CD47 (IAP) Introduction
      • 11.3.4 Akeso, Inc Revenue in CD47 (IAP) Business (2017-2022)
      • 11.3.5 Akeso, Inc Recent Developments
    • 11.4 Arch Oncology
      • 11.4.1 Arch Oncology Company Details
      • 11.4.2 Arch Oncology Business Overview
      • 11.4.3 Arch Oncology CD47 (IAP) Introduction
      • 11.4.4 Arch Oncology Revenue in CD47 (IAP) Business (2017-2022)
      • 11.4.5 Arch Oncology Recent Developments
    • 11.5 ImmuneOncia Therapeutics
      • 11.5.1 ImmuneOncia Therapeutics Company Details
      • 11.5.2 ImmuneOncia Therapeutics Business Overview
      • 11.5.3 ImmuneOncia Therapeutics CD47 (IAP) Introduction
      • 11.5.4 ImmuneOncia Therapeutics Revenue in CD47 (IAP) Business (2017-2022)
      • 11.5.5 ImmuneOncia Therapeutics Recent Developments
    • 11.6 I-MAB
      • 11.6.1 I-MAB Company Details
      • 11.6.2 I-MAB Business Overview
      • 11.6.3 I-MAB CD47 (IAP) Introduction
      • 11.6.4 I-MAB Revenue in CD47 (IAP) Business (2017-2022)
      • 11.6.5 I-MAB Recent Developments
    • 11.7 Sorrento Therapeutics
      • 11.7.1 Sorrento Therapeutics Company Details
      • 11.7.2 Sorrento Therapeutics Business Overview
      • 11.7.3 Sorrento Therapeutics CD47 (IAP) Introduction
      • 11.7.4 Sorrento Therapeutics Revenue in CD47 (IAP) Business (2017-2022)
      • 11.7.5 Sorrento Therapeutics Recent Developments
    • 11.8 Zai Lab
      • 11.8.1 Zai Lab Company Details
      • 11.8.2 Zai Lab Business Overview
      • 11.8.3 Zai Lab CD47 (IAP) Introduction
      • 11.8.4 Zai Lab Revenue in CD47 (IAP) Business (2017-2022)
      • 11.8.5 Zai Lab Recent Developments
    • 11.9 ImmuneOnco
      • 11.9.1 ImmuneOnco Company Details
      • 11.9.2 ImmuneOnco Business Overview
      • 11.9.3 ImmuneOnco CD47 (IAP) Introduction
      • 11.9.4 ImmuneOnco Revenue in CD47 (IAP) Business (2017-2022)
      • 11.9.5 ImmuneOnco Recent Developments
    • 11.10 Hengrui
      • 11.10.1 Hengrui Company Details
      • 11.10.2 Hengrui Business Overview
      • 11.10.3 Hengrui CD47 (IAP) Introduction
      • 11.10.4 Hengrui Revenue in CD47 (IAP) Business (2017-2022)
      • 11.10.5 Hengrui Recent Developments
    • 11.11 Beijing Mab-works
      • 11.11.1 Beijing Mab-works Company Details
      • 11.11.2 Beijing Mab-works Business Overview
      • 11.11.3 Beijing Mab-works CD47 (IAP) Introduction
      • 11.11.4 Beijing Mab-works Revenue in CD47 (IAP) Business (2017-2022)
      • 11.11.5 Beijing Mab-works Recent Developments
    • 11.12 Hanxbio
      • 11.12.1 Hanxbio Company Details
      • 11.12.2 Hanxbio Business Overview
      • 11.12.3 Hanxbio CD47 (IAP) Introduction
      • 11.12.4 Hanxbio Revenue in CD47 (IAP) Business (2017-2022)
      • 11.12.5 Hanxbio Recent Developments
    • 11.13 ALX Oncology
      • 11.13.1 ALX Oncology Company Details
      • 11.13.2 ALX Oncology Business Overview
      • 11.13.3 ALX Oncology CD47 (IAP) Introduction
      • 11.13.4 ALX Oncology Revenue in CD47 (IAP) Business (2017-2022)
      • 11.13.5 ALX Oncology Recent Developments
    • 11.14 Surface Oncology
      • 11.14.1 Surface Oncology Company Details
      • 11.14.2 Surface Oncology Business Overview
      • 11.14.3 Surface Oncology CD47 (IAP) Introduction
      • 11.14.4 Surface Oncology Revenue in CD47 (IAP) Business (2017-2022)
      • 11.14.5 Surface Oncology Recent Developments
    • 11.15 TG Therapeutics
      • 11.15.1 TG Therapeutics Company Details
      • 11.15.2 TG Therapeutics Business Overview
      • 11.15.3 TG Therapeutics CD47 (IAP) Introduction
      • 11.15.4 TG Therapeutics Revenue in CD47 (IAP) Business (2017-2022)
      • 11.15.5 TG Therapeutics Recent Developments
    • 11.16 EpicentRx
      • 11.16.1 EpicentRx Company Details
      • 11.16.2 EpicentRx Business Overview
      • 11.16.3 EpicentRx CD47 (IAP) Introduction
      • 11.16.4 EpicentRx Revenue in CD47 (IAP) Business (2017-2022)
      • 11.16.5 EpicentRx Recent Developments

    12 Analyst's Viewpoints/Conclusions

      13 Appendix

      • 13.1 Research Methodology
        • 13.1.1 Methodology/Research Approach
        • 13.1.2 Data Source
      • 13.2 Author Details

      Summary:
      Get latest Market Research Reports on CD47 (IAP). Industry analysis & Market Report on CD47 (IAP) is a syndicated market report, published as Global CD47 (IAP) Market Insights, Forecast to 2028. It is complete Research Study and Industry Analysis of CD47 (IAP) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      		$4,350.00
      		$8,700.00
      		3,471.30
      		6,942.60
      		4,062.90
      		8,125.80
      		679,774.50
      		1,359,549.00
      		363,181.50
      		726,363.00
      Credit card Logo
      Sample Question Discount Download PDF

      Related Reports

      Reason to Buy

      • Trusted By Leaders

        Top executives from leading companies purchase research reports from us. 

      • Shop With Confidence

        We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

      • Customer Centric

        Need assistance related to your research requirements? We are just a phone call or an email away.

      • Personalized Solutions

        Our experienced research specialists are here to help you locate the right reports for your need.

      • Secure Checkout

        Shop without being worried about safety & security of your transactions.
        •

      Request for Sample of this report

      Reports and Markets

      mcafree

      Contact Us

      +1-352-353-0818 (US)

      info@reportsandmarkets.com

      Support

      EMAIL US

      Newsletter

      KEEP UP TO DATE ON ALL THE LATEST REPORTS


      maxmind_logo